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Abstract 
Background: Bile acids (BAs) are known mediators of glucose metabolism that are 
altered in type 2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM). 
We hypothesised that post-prandial BA fractions are changed in women with Insulin 
resistance (IR) after recovery from GDM using homeostatic model assessment 
(HOMA-IR). 
Methods: 45 women median age 44(31-47) with previous GDM, including 20 with 
HOMA-IR >2.8 and 25 age-matched controls with HOMA-IR ≤ 2.8 were studied. After 
an overnight fast, all underwent an oral glucose tolerance test. Blood samples were 
collected at baseline and every 30min for 120min and analysed for glucose on 
automated platform and for total BAs, their conjugates and fractions using liquid-
chromatography tandem mass-spectrometry. Baseline samples were analysed for 
insulin on automated platform. Delta (Δ) change (difference between baseline and 
maximal post-prandial response) were calculated. Data is presented as median (IQR). 
Results: Fasting primary and unconjugated BAs were higher in women with HOMA-IR 
>2.8 vs. those with HOMA-IR ≤ 2.8 [0.24 (0.16-0.33) vs 0.06(0.04-0.22) µmol/L and 
0.91(0.56-1.84) µmol/L vs. 0.69(0.32-0.89) µmol/L respectively. ∆ taurine-conjugated 
BAs was higher in women with HOMA-IR ≤ 2.8 than those with HOMA-IR>2.8 
[0.33(0.20-0.54) vs 0.23(0.13-0.34) µmol/L]. Fasting glucose and non-12α-
hydroxylated BAs were negatively correlated in women with HOMA-IR >2.8 (all 
p<0.05). 
Conclusions: Following GDM, individuals with HOMA-IR >2.8 have altered 
conjugated and non-12α-hydroxylated fractions of BAs. It remains to be elucidated if 
the altered BA metabolism is a contributing factor to the pathogenesis or a 
consequence of GDM. 
 
 
Keywords: Bile Acids; Gestational Diabetes Mellitus; Insulin Resistance. 
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Introduction: 
 
Bile acids (BAs) play an important role in the digestion and absorption of fat and fat 
soluble vitamins in the small intestine, but also act as receptor-mediated hormones 
in the metabolism of glucose and energy homeostasis (1). Around 50% of daily 
cholesterol is converted to water-soluble BAs in the hepatocytes as primarily cholic 
acid (CA) and chenodeoxycholic acid (CDCA).  The major pathway of BA synthesis 
begins with the hydroxylation of cholesterol by cholesterol 7α-hydroxylase (CYP7A1). 
Subsequent metabolism via the intestinal bacterial flora on primary BAs, results in 
the formation of secondary BAs; deoxycholic acid (DCA), lithocholic acid (LCA) and 
ursodeoxycholic acid (UDCA). The glycine or taurine conjugation steps give rise to a 
total of 10 species of conjugated BAs. CA and DCA are 12α-hydroxylated BAs which 
contain a hydroxyle group on C12 position whereas in the non-12α-hydroxylated BAs 
(CDCA, DCA and LCA) this is absent (2). 
 
Bile acids signal through two receptors: the nuclear farnesoid X receptor (FXR) and 
the membrane receptor TGR5 (a G-protein coupled receptor) in the liver, intestine, 
gall bladder, adipose tissue, skeletal muscle and pancreas. FXR is involved in glucose 
homeostasis as well as lipid metabolism. In the intestine BAs stimulate L-cells via 
TGR5 receptors, activating the glycogen-like peptide 1 (GLP-1) pathway. The incretin 
GLP-1 promotes insulin secretion and enhances glucose metabolism (3). 
 
Gestational diabetes mellitus (GDM) is characterised by impaired glucose tolerance, 
recognised for the first time during pregnancy. It occurs in 3-5% of all pregnancies. 
Most women with GDM recover normal glucose metabolism after delivery, but are 
still at increased risk (~50%) of developing type 2 diabetes (T2DM) (4). Many studies 
have shown alterations in BA metabolism in patients with T2DM. Furthermore, 
modifications of the BA pool may help improve glycaemic control in patients with 
T2DM (3). Patients with uncontrolled T2DM have altered BA pool size and 
composition. Despite the discrepancies between studies, current data suggest that 
alterations in the metabolism of BAs may either be a cause or an effect of metabolic 
changes associated with T2DM (3).  
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Obstetric cholestasis (OC) is a pregnancy–induced complication affecting 1 in 200 
pregnant women. OC is characterised by maternal pruritus and raised bile acids and 
associated with impaired glucose tolerance test, dyslipidaemia and increased foetal 
growth leading to macrosomia. Aberrant homeostasis of BAs in OC may be 
responsible for impaired glucose metabolism, by affecting FXR and TGR5 signalling 
pathways (5). Few studies have examined the association between GDM and the 
composition and pool size of BAs during pregnancy in humans.  
 
Glucose tolerance tests are commonly used to define the clinical spectrum of 
glucose-related disorders. Individuals with pre-diabetes manifesting either as 
impaired fasting glucose or impaired glucose tolerance show an increased 
predisposition to develop T2DM. The gold standard method to assess glucose 
disposal and insulin resistance is euglycaemic hyperinsulinaemic clamp but this is 
impractical for large studies. A number of simpler surrogate measures of insulin 
resistance exist of which the Homeostasis Index of Insulin Resistance (HOMA-IR) is 
well established where HOMA-IR is calculated using the following equation: 
Fasting glucose (mmol/L) × Fasting insulin (mIU/L) / 22.5 
In the US National Health and Nutrition Survey (NHANES) individuals with HOMA-IR > 
2.8 (75th centile cut-off) showed an increased predisposition to develop T2DM and 
higher cardiovascular mortality (6). 
 
We hypothesised that BAs pool and composition as well as post-prandial BA 
metabolism are altered in women with previous history of GDM and with current 
insulin resistance (HOMA-IR > 2.8) compared with those with normal glucose 
metabolism. We also aimed to describe the relative kinetics of BAs in the fasting and 
post-prandial period in recipients of OGTT and examine the temporal correlation 
between fasting BAs with fasting insulin and glucose concentrations. We assessed BA 
profiles by measuring primary and secondary BAs , 12α-hydroxylated and non-12α-
hydroxylated fractions, as well as their glycine and taurine conjugates. 
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Subjects and Methods: 
- Subjects: 
This case-control study was approved by the local ethics committee of Devon and 
Cornwall REC / Plymouth University Hospital, UK (Ref: 1978, UKCRN number 4444) 
and was conducted according to the principles of the Helsinki declaration. All 
patients gave written informed consent. The power calculation was based on a 
previous study by our group comparing post-prandial BA response between patients 
with T2DM and normal individuals (7). 
 
Power calculation: 19 participants in each group are required if the mean post-
prandial delta (Δ) change (difference between baseline and maximal response) of 
total BA in women with HOMA-IR>2.8 is 4.28 µmol/L and women with HOMA-IR≤ 
2.8, 0.88 µmol/L with a standard deviation of 4.45 and 1.08 µmol/L respectively; at a 
significance level of 0.05 this would give a power of 90%.  
 
This case-control study recruited 45 women aged between 31 and 57 years with a 
history of previous GDM. All recruitment was carried out at Plymouth University 
Hospital. All were diagnosed with GDM 10 years prior to the study but had recovered 
to be euglycaemic at the time of study. The women were divided based on their 
HOMA-IR value into two groups in order to investigate whether there is a difference 
in post-meal BA response and other parameters between those with HOMA-IR > 2.8 
vs. ≤ 2.8 (control group). All women underwent a formal oral glucose tolerance test 
(OGTT). After an overnight fast an in-dwelling cannula was inserted into the 
antecubital fossa. 75 g glucose powder was dissolved in 200 ml warm water to be 
drunk over 5 minutes. Blood samples (serum and plasma) were collected at baseline 
and then at 30, 60, 90 and 120 minutes. Samples were stored for six months at -80 ◦C 
until analysis. Samples were analysed for glucose, primary and secondary BA as well 
as their glycine and taurine conjugates at all the time points. Insulin was measured 
on fasting samples. 
- Methods 
   1. BA measurement: 
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BAs were measured in three separate batches by an established in-house method 
using liquid chromatography tandem mass spectrometry (LC-MS/MS) in the 
department of Clinical Biochemistry (Viapath Analytics) at King’s College Hospital 
NHS Foundation Trust, London, UK. A Jasco high performance liquid chromatography 
(HPLC) system with three PU-pumps, MX-2080-32 solvent mixing module, AS-2059 
autosampler and CO-2067 column oven was used (Tokyo, Japan). The HPLC system 
was connected to an API 3200 triple quadrupole mass spectrometer (Applied 
Biosystems, Cheshire, UK) operated with an electrospray ionisation (ESI) source. All 
solvents and chemicals used were of analytical grade.  
       1.a. LC-MS/MS method 
LC-MS/MS assay was performed by modification of an existing protocol for plasma 
BA fractionation. Chromatography was performed using an Acentis fused-core C18 
analytical column (150 x4.6mm, particle size 2.7µm, Sigma-Aldrich) incubated at 
40°C. Mobile phase A was made from methanol + 0.012% formic acid (v/v) +5mM 
ammonium acetate (w/v) PH 4.50. Mobile phase B was made from deionised H2O + 
0.012% formic acid (v/v) + 5mM ammonium acetate (w/v) PH 7.31. Mobile phase 
gradients were delivered at a flow-rate of 0.6 mL/min, with 70% solvent A and 30% 
Solvent B at time 0 min, 95% solvent A and 5% solvent B at time 10 min and 95% 
solvent A and 5% solvent B at time 14 min.  Negative ion mass spectra of the 
fractionated BAs were recorded in multiple reaction-monitoring (MRM) mode.  The 
transitions were as following: 
 
m/z 391.2/391.2 for DC, CDC and UDC, 
m/z 407.1/407.1 for CA, 
m/z 375.2/375.2 for LC, 
m/z 448.2/74.1 for GDC, GCDC and GUDC, 
m/z 464.2/74.1 for GCA, 
m/z 432.1/74.1 for GLC, 
m/z 498.2/80.0 for TDC, TCDC and TUDC, 
m/z 514.0/80.0 for TCA, 
m/z 482.2/80.0 for TLC, 
m/z 395.2/395.2 for D4-DC, 
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m/z 452.1/74.1 for D4-GDC 
m/z 502.2/80.0 for D4-TDC. 
 
AnalystTM Software version 1.4.2 (Applied Biosystems) was used to acquire data and 
quantitation was carried out using peak area analysis corrected by comparison to 
internal standards (unconjugated, glycine- or taurine-conjugated d4-DCA). The 
column was washed between injections with 100µL of autosampler wash (70% (v/v) 
methanol, 30% (v/v) H2O). 
 
1. a. 1. Standard preparation 
A stock solution containing all BAs was prepared at a concentration of 4mM in 
methanol and used to make 20, 10, 5, 1, 0.1 and 0.05µM calibration standards by 
serial dilution in phosphate buffered saline (PBS). 250µL aliquots were stored at -
20°C. This method is linear for all the BAs between 0.17 and 10 µmol/L.  
. BAs with shown retention times for each fraction (Table 1) were adequately 
separated (Figure 1). 
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Figure 1. Bile acid chromatogram 
A chromatogram of a 1µM calibration standard showing all the bile acid analytes measured. CA Cholic 
acid; CDCA Chenodeoxycholic acid; d4-DCA Deoxycholic-2,2,4,4-d4 acid; d4-GDCA Glycodeoxycholic-
2,2,4,4-d4 acid; d4-TDCA Taurodeoxycholic-2,2,4,4-d4 acid; DCA Deoxycholic acid; GCA Glycocholic 
acid; GCDCA Glycochenodeoxycholic acid; GDCA Glycodeoxycholic acid; GLCA Glycolithocholic acid; 
GUDCA Glycoursodeoxycholic acid; LCA Lithocholic acid; TCA Taurocholic acid; TCDCA 
Taurochenodeoxycholic acid; TDCA Taurodeoxycholic acid ; TLCA Taurolithocholic acid; TUDCA 
Tauroursodeoxycholic acid; UDCA Ursodeoxycholic acid. 
 
Table 1. Bile acid retention times 
Column retention times for each of the bile acid fraction and internal standards. BA 
Bile acid. 
BA Retention time (min) 
TUDCA 3.91 
GUDCA 4.27 
TCA 4.85 
GCA 5.27 
TCDCA 6.53 
D4-TDCA 6.60 
TDCA 6.60 
UDCA 6.60 
GCDCA 6.60 
D4-GDCA 6.76 
GDCA 7.10 
CA 7.77 
TLCA 7.69 
GLCA 8.55 
CDCA 9.60 
D4-DCA 9.84 
DCA 9.83 
LCA 11.50 
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1. a. 2. Plasma sample preparation 
After extraction of BAs from plasma, 800µL of protein precipitating solution 
(acetonitrile containing the three internal standards) was added to 250µL plasma 
and vortex-mixed. Samples were centrifuged at 13,000 rpm for 10 minutes and 
900µL of the supernatant was removed. The supernatant was then dried down using 
compressed air at 60°C.  The residue was re-suspended in 250µL of a 50:50 (v/v) mix 
of the mobile phases (A&B). 10µL of this solution was injected onto the column 
(equivalent to 8.57µL of the original plasma sample). 
        1. b. Linearity checks were carried out with aliquots of pooled serum spiked with 
a combined BA stock at different concentrations and then serially diluted with 
pooled plasma.  Creation of a blank matrix proved difficult; endogenous BA could not 
be removed from plasma by charcoal stripping and BA was found to be present in 
bovine serum albumin (BSA).  Therefore the lower concentrations of the linear range 
were established by serial dilution with PBS solution.  The linear ranges were 
variable, but for the purpose of simplicity the range 0.1 - 10µM was used as this was 
valid for all bile acids with R2 value ranging from 0.9886 – 0.9999.Lower and upper 
limits of linearity in umol/L for each bile acid were as follows; CA, Cholic acid (0.08-
20.0); CDCA, Chenodeoxycholic acid (0.07-20.0); GCA, Glycocholic acid (0.1-20.0); 
GCDCA, Glycochenodeoxycholic acid (0.16-20.0); 
GDCA, Glycodeoxycholic acid (0.14-20.0); GLCA, Glycolithocholic acid (0.17-10.0); 
GUDCA, Glycoursodeoxycholic acid (0.06-20.0); LCA, Lithocholic acid (0.16-20.0);  
 TCA, Taurocholic acid (0.07-20.0); GCA, Glycocholic acid (0.1-20.0); TCDCA, 
Taurochenodeoxycholic acid (0.07-20.0); TDCA, Taurodeoxycholic acid (0.07-20.0); 
TLCA, Taurolithocholic acid (0.17-10.0); GLCA, Glycholithocholic acid (0.17-10.0); 
 TUDCA, Tauroursodeoxycholic acid (0.05-10.0); UDCA, Ursodeoxycholic acid (0.07-
10.0); DCA, Deoxycholic acid (0.08-10.0). The coefficient of variations (CV) for all BAs 
was acceptable and ranged from 3.6% to 12% at the lower limit of quantitation. The 
inter-assay CV was 3.6-8.0%. 
 
   1. c. interferences 
The most likely interferences are posed by ion suppression and isobaric 
contaminants. Ion suppression and isobaric contaminants exists between 2 to 2.5 
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minutes and after 14 minutes on each sample injection and thus is not a problem for 
this assay as the analytes elute between these times. No effects from the possible 
interferences such as haemolysis, lipaemia and icterus are seen in this method 
(recoveries ranged from 91 -109 %). We did not evaluate for any specific drug 
interferences but to our knowledge there are no known interactions. Use of high 
dose uersodeoxycholic acid can alter the BA pool and composition (8) however; none 
of the patients in our study were on this medication. 
     
 1. d. Carry-Over/ Carry-Under 
As a result of the incorporation of a wash run into the protocol and alteration of the 
auto-sampler flush settings and flush solution, no carry-over or carry-under was 
seen. 
    
  1. e. Recovery 
The method has good recovery for all concentrations ranging from 0.5, 1, 5 and 10 
µM for all BAs (recoveries ranging from 91– 115%). 
 
 2. Glucose measurement: 
Glucose was measured by enzymatic hexokinase method on the Siemens Advia 2400 
(Frimley, UK). Inter-assay CVs% were 1.6% at 6.4 mmol/l and 1.0% at 16.0 mmol/l.  
 
3. Insulin measurement: 
Insulin was measured by a two-site sandwich immunoassay using direct 
chemiluminometric method on the Siemens Centaur (Frimley, UK). Intra-assay CVs% 
were 4.6, 3.2 and 3.3 % and inter-assay precisions 5.9, 2.6 and 4.8% at 14.68, 45.72 
and 124.51 mU/L respectively. 
 
Statistical analysis 
 
Statistical analysis was performed using Analyse-It® version 2 (Leeds, UK). Data were 
tested for normality using the Shapiro-Wilk W test with a confidence interval of 95%. 
Given the nonparametric data, groups were compared using Mann Whitney U test 
and correlations by Spearman’s Rank. The 12α-hydroxylated and non-12α-
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hydroxylated BA fractions, HOMA-IR and delta (Δ) change (difference between 
baseline and maximal post-prandial response) were calculated. All data is reported 
as median and inter-quartile range (IQR). A p value ≤ 0.05 was taken as statistically 
significant. 
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Results: 
 
Patient characteristics are shown in Table 1 and correlation studies between women 
with HOMA-IR ≤2.8 and >2.8 in Table 2. Body mass indices and fasting insulin 
concentrations were higher in individuals with insulin resistance (both p<0.001). 
Fasting glucose concentrations were similar between the two groups (HOMA-IR ≤2.8, 
p=0.08 and >2.8, p=0.13). 
Table 2. Comparisons of the analytes between women with HOMA-IR ≤2.8 and >2.8.; 
HOMA-IR Homeostasis model assessment-estimated insulin resistance index; F 
Fasting; BAs Bile acids. Δ Delta change (The difference between basal and maximal 
post-prandial response); Values are median concentration with IQR. 
                   
                         Comparisons 
 
HOMA-IR ≤ 2.8 
(n=25) 
 
HOMA-IR> 2.8 
(n=20) 
 
p-value 
Age (year) 42 (38-44) 43 (39-47) 0.51 
BMI (Kg/m
2
) 25 (23-27) 30 (27-37) <0.001 
Insulin (mIU/L) 5.61 (3.8-8.2) 161 (12.9-9) <0.0001 
Glucose (mmol/L) 5.0 (4.4-4.8) 5.0 (4.6-5.6) 0.08 
HOMA-IR 1.2 (0.8-1.6) 3.6 (3.1-4.3) <0.0001 
Fasting total BAs 
F total BAs (µmol/L) 
 
1.53 (1.12-1.91) 1.43(1.04 -1.98) 0.63 
F total primary BAs (µmol/L) 
 
0.06 (0.04-0.22) 0.24 (0.16-0.33) 0.004 
F total secondary BAs (µmol/L) 
 
0.19 (0.14-0.23) 0.16 (0.14-0.32) 0.83 
F total glycine-conjugated BAs (µmol/L) 
 
0.89 (0.54 -1.38) 0.80 (0.49-1.22) 0.86 
F total taurine-conjugated BAs (µmol/L ) 0.27 (0.16-0.41) 0.21(0.17-0.29) 0.56 
F total unconjugated BAs (µmol/L) 0.69 (0.32-0.89) 0.91 (0.56-1.84) 0.02 
F total 12α-hydroxylated BAs (µmol/L) 0.21 (0.15-0.44) 0.22 (0.18-0.29) 0.97 
F total non12α-hydroxylated BAs (µmol/L) 0.16 (0.08-0.21) 0.19 (0.14-0.22) 0.17 
∆ Total BAs 
∆ total BAs (µmol/L) 2.61 (1.74-3.79) 2.62 (1.85-4.50) 0.96 
∆ total primary BAs (µmol/L) 0.13 (0.03-0.50) 0.29 (0.07-0.60) 0.25 
∆ total secondary BAs (µmol/L) 0.18 (0.07-0.31) 0.21 (0.05-0.55) 0.43 
∆total glycine-conjugated BAs (µmol/L) 2.24 (1.34-2.89) 1.76 (1.42-2.74) 0.64 
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∆total taurine-conjugated BAs (µmol/L) 0.33 (0.20-0.54) 0.23 (0.13-0.34) 0.03 
∆total 12α-hydroxylated BAs (µmol/L) 0.15 (0.05-0.53) 0.09 (0.04-0.35) 0.63 
∆ total non12α-hydroxylated BAs (µmol/L) 0.09(0.025-0.24) 0.10 (0.06-0.29) 0.35 
 
 
 
Fasting primary BAs and ∆taurine-conjugated BA were higher in women with HOMA-
IR≤ 2.8 (p=0.03). No difference was seen between the two groups in post-prandial 
changes of primary and secondary BAs, glycine-conjugated, 12α-hydroxylated and 
non-hydroxylated fractions (all p>0.05). 
Table 3. Correlation studies between women with HOMA-IR ≤2.8 and >2.8.; HOMA-
IR Homeostasis model assessment-estimated insulin resistance index; Values are 
median concentration with IQR. 
 
There was a positive correlation between BMI and secondary BA concentration and 
between fasting insulin and HOMA-IR with glycine- and taurine-conjugated BAs in 
individual with insulin resistance (Table 2) (All p≤0.05). A negative correlation was 
observed between fasting glucose and non-12α-hydroxylated BAs in individuals with 
HOMA-IR>2.8. 
 
Correlations 
 
HOMA-IR ≤ 2.8 
(n=25) 
 
HOMA-IR > 2.8 
(n=20) 
BMI secondary BAs  R
2
= 0.44,   p=0.05 R
2
= -0.41,   p=0.10 
BMI primary BAs  R
2
= 0.17,   p=0.42 R
2
= -0.30,   p=0.23 
Glucose  total primary BAs  R
2
= 0.32,  p=0.11 R
2
= -0.30,   p=0.23 
Glucose  total secondary BAs  R
2
= -0.01,  p=0.95 R
2
= -0.41,   p=0.10 
Glucose   12α-hydroxylated BAs  R
2
=  0.35,  p=0.07 R
2
= -0.12,   p=0.64 
Glucose 12α-non-hydroxylated BAs  R
2
= 0.22,   p=0.26 R
2
= - 0.54,   p=0.03 
Insulin glycine-conjugated BAs  R
2
= 0.51,   p=0.007 R
2
= 0.02,   p=0.91 
Insulin   taurine-conjugated BAs  R
2
= 0.54,   p=0.003 R
2
= -0.11,   p=0.64 
HOMA-IR  glycine-conjugated BAs  R
2
= 0.41,   p=0.03 R
2
= 0.36,   p=0.15 
HOMA-IR taurine-conjugated BAs  R
2
= 0.44,   p=0.03 R
2
= 0.15,   p=0.6 
HOMA-IR  12α-hydroxylated BAs  R
2
=  0.04,  p=0.84 R
2
= 0.22,   p=0.38 
HOMA-IR   non-12α-hydroxylated BAs  R
2
= 0.09,   p=0.67 R
2
= -0.06, p=0.81 
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Median concentration of total BAs and total taurine conjugated BAs as well as other 
BA components were measured following a test meal in women with HOMA-IR ≤ 2.8 
and >2.8 at different time points. The post-prandial response of total and total 
taurine-conjugated BAs between the HOMA-IR≤ 2.8 and >2.8 are shown in Figures 1 
and 2 respectively. Figure 1 shows that total BAs concentration was not different at 
given time points between the case and control group, however; this difference was 
observed in total taurine-conjugated BAs concentrations between the two groups as 
presented in Figure 2 and shown in Table 1. 
 
 
 
 
 
 
Figure 2. Post-prandial median total BAs in women with HOMA-IR ≤ 2.8 and >2.8. 
Median concentration of total BAs following a test meal in women with HOMA-IR ≤ 
2.8 and >2.8 at different time points (minutes). BAs Bile acids; HOMA-IR Homeostasis 
model assessment-estimated insulin resistance index. 
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Figure 3. Post-prandial median total taurine-conjugated BAs in women with HOMA-
IR ≤ 2.8 and >2.8.  . Median concentration of taurine-conjugated BAs following a test 
meal in women with HOMA-IR ≤ 2.8 and >2.8 at different time points (minutes). BAs 
Bile acids; HOMA-IR Homeostasis model assessment-estimated insulin resistance 
index. 
 
 
Discussion 
 
Our study demonstrates that BA metabolism is altered in those with continued 
insulin resistance after GDM. Fasting total primary BAs and total unconjugated BAs 
were increased in women with HOMA-IR >2.8. The Post-prandial changes of taurine-
conjugated BAs were lower in women with HOMA-IR >2.8. A recent study has shown 
that total taurine-conjugated BAs show an inverse association with glycaemic status 
with a strong discriminative power between control and GDM pregnant women (4) 
as was seen in this study. Another study reported that concentrations of total 
taurine-conjugated BAs were higher in patients with T2DM compared with 
normoglycaemic controls (10) but our study did not find any difference between 
fasting taurine-conjugated BAs concentration in women between the two groups. 
However, it is worth considering that our study samples were taken from non-
diabetic individuals which may explain the discordance between the reported data. 
Nonetheless, post-prandial taurine-conjugated BAs response was increased in the 
individuals with HOMA-IR≤ 2.8 in keeping with the findings of Wewalka et al (9). 
Further analysis with a larger cohort will possibly better explain trends in BA species.  
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Pregnancies associated with maternal insulin resistance may progress towards GDM 
(4). BA metabolism is altered in T2DM (3) but, little is known about BAs metabolism 
and composition in normal pregnancies or GDM.  Recent studies have focused in BAs 
subspecies.  The enzymes CYP7A1 (rate limiting) and CYP8B1 (12α hydroxylase) drive 
the BA pool and composition respectively (10). Non-12α-hydroxylated primary BA, 
CDCA, and secondary BA LCA have greater affinity for the receptors FXR and TGR5 
respectively (11). Our study investigated the changes of 12α-hydroxylated and non 
12α-hydroxylated BAs in a group of women with a history of GDM with HOMA-IR> 
2.8 compared to those with normalised insulin metabolism. Studies suggest that 
12α-hydroxylated BAs are higher in insulin resistant individuals compared with 
healthy subjects (10, 11). In our study no difference was seen between the fasting 
concentrations of total 12α-hydroxylated and non 12α-hydroxylated BAs between 
the two groups. However, fasting total non-12α-hydroxylated BAs showed a negative 
correlation with glucose in women with HOMA-IR>2.8. Thus an increase in non 12α-
hydroxylated BA may contribute to improved glucose metabolism after GDM. 
 
Intestinal bacterial flora converts primary BAs to secondary BAs (2). Gut microbiota 
have been shown to be altered in a number of metabolic conditions such as obesity, 
diabetes and cardiovascular disease (1, 9). A study showed that T2DM and increased 
resistance to insulin associate with elevated secondary BA, DCA and decreased 
primary BA, CDCA likely due to altered intestinal flora activity (1, 11). This study did 
not investigate changes in intestinal flora in GDM. Our findings are compatible with 
those studies in showing an increase in fasting total primary BAs in the group of 
individuals with HOMA-IR> 2.8 compared with subjects with HOMA-IR≤ 2.8.  
 
A positive correlation was seen between BMI and fasting total secondary BAs in 
subjects with HOMA-IR≤ 2.8.  A study in obese subjects showed that GLCA (a 
conjugated secondary BA) levels decreased after bariatric surgery (12).  The relative 
composition of the gut flora during early life can predict the subsequent 
development of obesity (13). Levels of lipopolysaccharide (LPS), an endotoxin 
derived from the cell walls of a gram-negative bacterium are increased in obese 
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individuals. Changes in LPS and intestinal bacterial flora after bariatric surgery have 
been postulated to alter BA metabolism (13). In our study total primary BAs in the 
group were increased in patients with continuing insulin resistance (HOMA-IR >2.8) 
compared with those with normal glucose metabolism. 
 
Limitations and further work 
The power calculation was adequate to compare the changes in primary and 
secondary BAs but maybe inadequate for multiple comparisons and to resolve 
changes in individual BAs. Hence, some of the potentially significant changes in the 
concentrations of BA fractions may have resulted only on relative changes in our 
study. Furthermore individuals with HOMA-IR >2.8 had higher BMI values compared 
to those with HOMA-IR ≤2.8 and on average were more overweight to obese. 
Therefore, the altered BA metabolism could be either cause or effect of higher BMI. 
 
A meta-analysis suggested that elevated concentrations of inflammatory markers 
such as interleukin-6 (IL-6) and C-reactive protein (CRP) are associated with 
increased risk of T2DM (14). BAs are known to have regulatory impacts on the innate 
immune system. Innate immune system includes macrophages which secrete 
inflammatory markers such as IL-6 and tumour necrosis factor-α (TNF-α) (15). We did 
not measure inflammatory markers in this study. A history of concomitant 
medications and other co-morbidities were not well documented in our cohort. 
 
Alterations in sex hormone metabolism are associated with elevated levels of BAs in 
OC (16). Measurements of oestrogen, progesterone and their metabolites may 
provide further insights into alterations of BAs and glucose metabolism during 
pregnancy. This study was performed in a post-partum cohort diagnosed with GDM 
in their previous pregnancies 10 years ago. More informative studies might be useful 
during pregnancy or immediately post-partum.  
 
In patients with previous GDM this study shows that BAs metabolism is altered in 
those with insulin resistance (HOMA-IR >2.8) compared with those who have lower 
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HOMA-IR values. Changes in 12α-hydroxylated and non-12α-hydroxylated BAs in 
women with HOMA-IR ≤2.8 or >2.8 were investigated. In women with HOMA-IR>2.8 
a negative correlation between glucose concentrations and non-12α-hydroxylated 
BAs were seen, which is compatible with the hypothesis of alteration of non 12α-
hydroxylated fractions of BAs in insulin resistance. Post-prandial dynamic changes in 
BAs after GDM were investigated. Women with HOMA-IR≤2.8 had elevated post-
prandial taurine-conjugated BAs response compared with those with higher HOMA-
IR.  
 
In conclusion, following GDM, individuals with HOMA-IR values of >2.8 have altered 
conjugated forms of BAs as well as non-12α-hydroxylated fractions compared to 
those in whom insulin metabolism had normalised. However, it remains to be 
elucidated if the altered BA metabolism is a contributing factor to the pathogenesis 
or a consequence of GDM. 
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